Related references
Note: Only part of the references are listed.Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment
Cyrus Chargari et al.
CANCER TREATMENT REVIEWS (2011)
HER2 genetic heterogeneity in breast carcinoma
Christian Oehlschlegel et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer
Julie M. Wu et al.
HUMAN PATHOLOGY (2010)
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype
So Yeon Park et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
Matteo Brunelli et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status
Raymond Tubbs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prediction of HER2 gene status in Her2 2+invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
Frederic Chibon et al.
MODERN PATHOLOGY (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Cardiac toxicity of ErbB2-targeted therapies: What do we know?
Edith A. Perez
CLINICAL BREAST CANCER (2008)
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas
C. B. Nunes et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases
Mamatha Chivukula et al.
MODERN PATHOLOGY (2008)
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer
P. H. Cottu et al.
ANNALS OF ONCOLOGY (2008)
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
Louis R. Garrison et al.
CANCER (2007)
Intratumoral heterogeneity of HER2/neu in breast cancer -: A rare event
Wedad Hanna et al.
BREAST JOURNAL (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intratumoral heterogeneity of HER-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray
Sandra J. Shin et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining
JT Lewis et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Calibration of immunohistochemistry for assessment of HER2 in breast cancer:: results of the French Multicentre GEFPICS Study
A Vincent-Salomon et al.
HISTOPATHOLOGY (2003)
The clinical evaluation of HER-2 status: which test to use?
J Bartlett et al.
JOURNAL OF PATHOLOGY (2003)
Marked intratumoral heterogeneity of c-myc and CyclinD1 but not of c-erbB2 amplification in breast cancer
S Glöckner et al.
LABORATORY INVESTIGATION (2002)
When is a tumor marker ready for prime time?: A case study of c-erbB-2 as a predictive factor in breast cancer
H Yamauchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables
S Ménard et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
